219 related articles for article (PubMed ID: 23583010)
1. The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial.
Ghanizadeh A; Nikseresht MS; Sahraian A
Schizophr Res; 2013 Jun; 147(1):110-115. PubMed ID: 23583010
[TBL] [Abstract][Full Text] [Related]
2. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.
McElroy SL; Winstanley E; Mori N; Martens B; McCoy J; Moeller D; Guerdjikova AI; Keck PE
J Clin Psychopharmacol; 2012 Apr; 32(2):165-72. PubMed ID: 22367654
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
Henderson DC; Copeland PM; Daley TB; Borba CP; Cather C; Nguyen DD; Louie PM; Evins AE; Freudenreich O; Hayden D; Goff DC
Am J Psychiatry; 2005 May; 162(5):954-62. PubMed ID: 15863798
[TBL] [Abstract][Full Text] [Related]
4. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
[TBL] [Abstract][Full Text] [Related]
5. Zonisamide for weight loss in obese adults: a randomized controlled trial.
Gadde KM; Franciscy DM; Wagner HR; Krishnan KR
JAMA; 2003 Apr; 289(14):1820-5. PubMed ID: 12684361
[TBL] [Abstract][Full Text] [Related]
6. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Wu RR; Zhao JP; Jin H; Shao P; Fang MS; Guo XF; He YQ; Liu YJ; Chen JD; Li LH
JAMA; 2008 Jan; 299(2):185-93. PubMed ID: 18182600
[TBL] [Abstract][Full Text] [Related]
7. Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study.
de Silva VA; Dayabandara M; Wijesundara H; Henegama T; Gunewardena H; Suraweera C; Hanwella R
J Psychopharmacol; 2015 Dec; 29(12):1255-61. PubMed ID: 26510448
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive α-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics: a double-blind randomized placebo-controlled study.
Kim NW; Song YM; Kim E; Cho HS; Cheon KA; Kim SJ; Park JY
Int Clin Psychopharmacol; 2016 Sep; 31(5):265-74. PubMed ID: 27276401
[TBL] [Abstract][Full Text] [Related]
9. Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate.
Sliwa JK; Fu DJ; Bossie CA; Turkoz I; Alphs L
BMC Psychiatry; 2014 Feb; 14():52. PubMed ID: 24559194
[TBL] [Abstract][Full Text] [Related]
10. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.
Baptista T; Martínez J; Lacruz A; Rangel N; Beaulieu S; Serrano A; Arapé Y; Martinez M; de Mendoza S; Teneud L; Hernández L
Can J Psychiatry; 2006 Mar; 51(3):192-6. PubMed ID: 16618011
[TBL] [Abstract][Full Text] [Related]
11. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
Poyurovsky M; Isaacs I; Fuchs C; Schneidman M; Faragian S; Weizman R; Weizman A
Am J Psychiatry; 2003 Feb; 160(2):297-302. PubMed ID: 12562576
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.
Klein DJ; Cottingham EM; Sorter M; Barton BA; Morrison JA
Am J Psychiatry; 2006 Dec; 163(12):2072-9. PubMed ID: 17151157
[TBL] [Abstract][Full Text] [Related]
13. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study.
Wu RR; Jin H; Gao K; Twamley EW; Ou JJ; Shao P; Wang J; Guo XF; Davis JM; Chan PK; Zhao JP
Am J Psychiatry; 2012 Aug; 169(8):813-21. PubMed ID: 22711171
[TBL] [Abstract][Full Text] [Related]
14. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.
Smith RC; Maayan L; Wu R; Youssef M; Jing Z; Sershen H; Szabo V; Meyers J; Jin H; Zhao J; Davis JM
Psychopharmacology (Berl); 2018 Dec; 235(12):3545-3558. PubMed ID: 30382354
[TBL] [Abstract][Full Text] [Related]
15. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain.
Ko YH; Joe SH; Jung IK; Kim SH
Clin Neuropharmacol; 2005; 28(4):169-75. PubMed ID: 16062095
[TBL] [Abstract][Full Text] [Related]
16. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
[TBL] [Abstract][Full Text] [Related]
18. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.
Fleischhacker WW; Heikkinen ME; Olié JP; Landsberg W; Dewaele P; McQuade RD; Loze JY; Hennicken D; Kerselaers W
Int J Neuropsychopharmacol; 2010 Sep; 13(8):1115-25. PubMed ID: 20459883
[TBL] [Abstract][Full Text] [Related]
19. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.
Carrizo E; Fernández V; Connell L; Sandia I; Prieto D; Mogollón J; Valbuena D; Fernández I; de Baptista EA; Baptista T
Schizophr Res; 2009 Aug; 113(1):19-26. PubMed ID: 19515536
[TBL] [Abstract][Full Text] [Related]
20. Zonisamide-induced weight loss in schizophrenia: case series.
Yang J; Lee MS; Joe SH; Jung IK; Kim SH
Clin Neuropharmacol; 2010; 33(2):104-6. PubMed ID: 19935403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
